{
    "root": "31352593-a65e-3b4e-e063-6294a90a49f9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paliperidone",
    "value": "20250325",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18012"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)",
            "code": "5KY68S2577",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 100000",
            "code": "V46Y6OJ5QB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "PALIPERIDONE",
            "code": "838F01T721",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82978"
        }
    ],
    "indications": {
        "text": "paliperidone extended-release tablets atypical antipsychotic agent indicated treatment schizophrenia ( 1.1 ) adults : efficacy established three 6-week trials one maintenance trial . ( 14.1 ) adolescents ( ages 12 17 ) : efficacy established one 6-week trial . ( 14.1 ) treatment schizoaffective disorder monotherapy adjunct mood stabilizers and/or antidepressants . ( 1.2 ) efficacy established two 6-week trials adult patients . ( 14.2 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "schizoaffective disorder (DOID:5418)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5418"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initial dose recommended dose maximum dose schizophrenia - adults ( 2.1 ) 6 mg/day 3 12 mg/day 12 mg/day schizophrenia-adolescents ( 2.1 ) weight < 51 kg 3 mg/day 3 6 mg/day 6 mg/day weight \u2265 51 kg 3 mg/day 3 12 mg/day 12 mg/day schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3 12 mg/day 12 mg/day tablet swallowed whole chewed , divided , crushed . ( 2.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "schizoaffective disorder (DOID:5418)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5418"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "paliperidone extended-release tablets , 1.5 mg , supplied brown , round , biconvex tablets , debossed \u201c \u201d \u201c 80 \u201d one side plain side . available follows : bottles 30 : ndc 65162-280-03 bottles 90 : ndc 65162-280-09 paliperidone extended-release tablets , 3 mg , supplied white , round , biconvex tablets , debossed \u201c \u201d \u201c 81 \u201d one side plain side . available follows : bottles 30 : ndc 65162-281-03 bottles 90 : ndc 65162-281-09 paliperidone extended-release tablets , 6 mg , supplied light beige , round , biconvex tablets , debossed \u201c \u201d \u201c 82 \u201d one side plain side . available follows : bottles 30 : ndc 65162-282-03 bottles 90 : ndc 65162-282-09 paliperidone extended-release tablets , 9 mg , supplied pink , round , biconvex tablets , debossed \u201c \u201d \u201c 83 \u201d one side plain side . available follows : bottles 30 : ndc 65162-283-03 bottles 90 : ndc 65162-283-09 storage handling store 20\u00b0 25\u00bac ( 68\u00b0 77\u00baf ) ; excursions permitted 15\u00b0 30\u00bac ( 59\u00b0 86\u00baf ) [ usp controlled room temperature ] . protect moisture . keep reach children .",
    "adverseReactions": "paliperidone extended-release tablets contraindicated patients known hypersensitivity either paliperidone risperidone , excipients paliperidone extended-release tablet formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "indications_original": "Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia (1.1) Adults: Efficacy was established in three 6-week trials and one maintenance trial. (14.1) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. (14.1) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. (1.2) Efficacy was established in two 6-week trials in adult patients. (14.2)",
    "contraindications_original": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults (2.1) 6 mg/day 3 to 12 mg/day 12 mg/day Schizophrenia-adolescents (2.1) Weight < 51 kg 3 mg/day 3 to 6 mg/day 6 mg/day Weight \u2265 51 kg 3 mg/day 3 to 12 mg/day 12 mg/day Schizoaffective disorder - adults (2.2) 6 mg/day 3 to 12 mg/day 12 mg/day Tablet should be swallowed whole and should not be chewed, divided, or crushed. (2.3)",
    "warningsAndPrecautions_original": "Paliperidone extended-release tablets,\n \n  1.5 mg, are supplied as brown, round, biconvex tablets, debossed \u201cAN\u201d over \u201c80\u201d on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-280-03 \n    Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-280-09\n \n                  Paliperidone extended-release tablets,\n \n  3 mg, are supplied as white, round, biconvex tablets, debossed \u201cAN\u201d over \u201c81\u201d on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-281-03 \n    Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-281-09\n \n                  Paliperidone extended-release tablets,\n \n  6 mg, are supplied as light beige, round, biconvex tablets, debossed \u201cAN\u201d over \u201c82\u201d on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30:\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-282-03 \n    Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-282-09\n \n                  Paliperidone extended-release tablets,\n \n  9 mg, are supplied as pink, round, biconvex tablets, debossed \u201cAN\u201d over \u201c83\u201d on one side and plain on the other side. \n    They are available as follows:\n\n \n                  Bottles of 30: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-283-03 \n    Bottles of 90:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 65162-283-09\n \n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00b0 to 25\u00baC (68\u00b0 to 77\u00baF); excursions permitted between 15\u00b0 to 30\u00baC (59\u00b0 to 86\u00baF) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Keep out of reach of children.",
    "adverseReactions_original": "Paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablet formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone.",
    "drug": [
        {
            "name": "Paliperidone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_82978"
        }
    ]
}